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Objective: Loss of function mutations in PINK1 typically lead to early onset Parkinson disease (PD). Zebrafish (Danio
rerio) are emerging as a powerful new vertebrate model to study neurodegenerative diseases. We used a pink1
mutant (pink2=2) zebrafish line with a premature stop mutation (Y431*) in the PINK1 kinase domain to identify molec-
ular mechanisms leading to mitochondrial dysfunction and loss of dopaminergic neurons in PINK1 deficiency.
Methods: The effect of PINK1 deficiency on the number of dopaminergic neurons, mitochondrial function, and mor-
phology was assessed in both zebrafish embryos and adults. Genome-wide gene expression studies were undertaken
to identify novel pathogenic mechanisms. Functional experiments were carried out to further investigate the effect of
PINK1 deficiency on early neurodevelopmental mechanisms and microglial activation.
Results: PINK1 deficiency results in loss of dopaminergic neurons as well as early impairment of mitochondrial func-
tion and morphology in Danio rerio. Expression of TigarB, the zebrafish orthologue of the human, TP53-induced gly-
colysis and apoptosis regulator TIGAR, was markedly increased in pink2=2 larvae. Antisense-mediated inactivation of
TigarB gave rise to complete normalization of mitochondrial function, with resulting rescue of dopaminergic neurons
in pink2=2 larvae. There was also marked microglial activation in pink2=2 larvae, but depletion of microglia failed to
rescue the dopaminergic neuron loss, arguing against microglial activation being a key factor in the pathogenesis.
Interpretation: Pink12=2 zebrafish are the first vertebrate model of PINK1 deficiency with loss of dopaminergic neu-
rons. Our study also identifies TIGAR as a promising novel target for disease-modifying therapy in PINK1-related PD.
ANN NEUROL 2013;74:837–847
Autosomal recessively inherited, loss of functionmutations in PTEN-induced kinase 1 (PINK1) typi-
cally lead to early onset Parkinson disease (EOPD).1 The
PINK1 protein is expressed ubiquitously throughout the
human brain.2 Impaired mitochondrial function and
morphology have been described in both human PINK1
mutant patient tissue and different PINK1-deficient in
vitro or in vivo model systems.3,4 PINK1 has also been
implicated in oxidative stress defense, mitophagy, and the
regulation of mitochondrial calcium homeostasis.3–5
View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.23999
Received Nov 29, 2012, and in revised form Jul 30, 2013. Accepted for publication Aug 3, 2013.
Address correspondence to Dr Bandmann, Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a
Glossop Road, Sheffield S10 2HQ, United Kingdom. E-mail: o.bandmann@sheffield.ac.uk
From the 1Medical Research Council Centre for Developmental and Biomedical Genetics, University of Sheffield, Sheffield, United Kingdom; 2Sheffield
Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom; 3Zoological Institute, Braunsch-
weig University of Technology, Braunschweig, Germany; 4Department of Morphology, Biochemistry, Physiology, and Animal Productions, Section of
Morphology, University of Messina, Polo Universitario dell’Annunziata, Messina, Italy; 5Medical Research Council Protein Phosphorylation and Ubiquityla-
tion Unit, College of Life Sciences, University of Dundee, Dundee, United Kingdom; 6Helmholtz Center, Institute of Developmental Genetics, Munich,
Germany; 7College of Medicine, Dentistry, and Nursing, University of Dundee, Dundee, United Kingdom; 8Department of Mitochondrial Biology, Buch-
mann Institute for Molecular Life Sciences, Frankfurt am Main, Germany; 9Department of Mitochondrial Biology, Center for Molecular Medicine, Goethe
University, Frankfurt am Main, Germany; 10Lee Kong Chian School of Medicine, Nanyang Technological University/Imperial College London, Singapore.
Additional supporting information can be found in the online version of this article.
VC 2013 American Neurological Association 837
However, the precise mechanisms leading to neuronal
cell death remain unclear. Pink1 knockout mice do not
develop loss of dopamine (DA) neurons in the substantia
nigra and can therefore only be of limited use in investi-
gating the mechanisms leading to neuronal cell death in
human Parkinson disease (PD).6
Zebrafish are increasingly being used to model neu-
rodegenerative diseases.7 As vertebrates, they are closer to
humans than other genetically tractable model organisms
such as Drosophila or Caenorhabditis elegans. Zebrafish
embryos develop externally, are transparent, and have a
well-characterized DA nervous system.8 To date, investi-
gations of the functional consequences of PD gene dys-
function in zebrafish have relied on the injection of
morpholino antisense oligonucleotides (MOs).7 A major
limitation of this approach is that MOs injected into the
fertilized egg lose their effect within 3 to 5 days postferti-
lization, thus precluding investigation of the morphologi-
cal, biochemical, or behavioral effects of gene
dysfunction at larval and adult stages. In addition, mor-
pholinos are frequently associated with nonspecific, off-
target effects.9 Previous studies using the MO strategy to
investigate the effects of PINK1 deficiency in zebrafish
have led to conflicting results.10–12
Using the targeting induced local lesions in
genomes (TILLING) approach, we have now established
a stable line carrying a premature stop mutation in the
kinase-encoding domain of pink1 (Y431*), the zebrafish
orthologue of human PINK1. We provide confirmation
that this mutation leads to inactivation of PINK1 cata-
lytic activity and decreased mRNA stability. We further
demonstrate that PINK1 deficiency in Danio rerio results
in highly specific abnormalities in early development,
which closely match the biochemical and morphological
manifestations of the human disease, with persisting loss
of dopaminergic neurons in adulthood and also persist-
ing mitochondrial impairment. Genome-wide gene
expression studies identified upregulation of TigarB, the
zebrafish homologue of the TP53-induced glycolysis and
apoptosis regulator (TIGAR).13 Remarkably, TigarB
knockdown resulted in normalization of mitochondrial
function and complete rescue of ascending dopaminergic
neurons. Modulation of TIGAR-related mechanisms may
therefore be a promising novel strategy to develop
disease-modifying therapy for PINK1-related PD.
Materials and Methods
All zebrafish husbandry and experimental procedures were per-
formed in accordance with the UK Home Office Animals (Sci-
entific Procedures) Act (project license PPL 40=3402). Details
of animal maintenance, mutagenesis, and identification of the
described pink1 mutation are summarized in the Supplementary
Materials and Methods.
In Vitro Kinase Assay of PINK1 and mRNA
Stability
All PINK1 enzymes used in this study were expressed in Esche-
richia coli as full-length maltose-binding protein fusion proteins
as previously described.14 Briefly, BL21 codon1 transformants
were grown at 37C then shifted to 16C and induced with
250lM isopropyl b-D-thiogalactoside at OD600 5 0.5. Cul-
tures were then grown for a further 15 to 16 hours at 16C.
Cells were lysed by sonication, and lysates were clarified by cen-
trifugation at 30,000 3 g for 30 minutes at 4C followed by
incubation with 1ml per liter of culture of amylose resin for
1.5 hours at 4C. The resin was washed thoroughly, and pro-
teins were then eluted and dialyzed overnight at 4C into stor-
age buffer. Kinase assays were set up in a volume of 40ll, with
substrates at 2lM and all kinases at 1lg in 50mM Tris-HCl
(pH 7.5), 0.1mM ethyleneglycoltetraacetic acid, 10mM MgCl2,
2mM dithiothreitol, and 0.1mM [c-32P]adenosine triphosphate
(ATP). Assays were incubated at 30C with shaking at
1,200rpm and terminated after 30 minutes by addition of
sodium dodecyl sulfate (SDS) sample buffer. Reaction mixtures
were resolved by SDS–polyacrylamide gel electrophoresis. Pro-
teins were detected by Coomassie staining, and incorporation
of [c-32P]ATP into substrates was analyzed by autoradiography.
RNA was extracted from wt and pink12=2 embryos at 3
days postfertilization (dpf). A Verso cDNA synthesis kit
(Thermo Scientific, Waltham, MA) was used to generate the
cDNA. Transcript levels of pink1 were quantified by quantita-
tive polymerase chain reaction (qPCR) using primers R (50-
CTGATGACGTTCAGCTGGTG) and L (50-CCACAGACT-
GATGTGCAGGA) at an annealing temperature of 60C.
Quantification of Dopaminergic Neurons
in Zebrafish Larvae and Adult Brains
Whole mount tyrosine hydroxylase (TH) and DA transport
protein (DAT) in situ hybridization was undertaken as previ-
ously described.15 The mean number of these diencephalic
dopaminergic neurons for wt and pink12=2 was calculated over
3 independent experiments (n 5 10 of embryos per genotype
and experiment). Nine adult pink12=2 and a further 9 wild-
type controls (wild-type siblings) were sacrificed at the age of
18 months. The number of dopaminergic neurons in these
adult brains was determined by counting the number of TH-
positive neurons in axial sections within the DC3 and DC4
cluster (see Supplementary Materials and Methods for further
details).
Mitochondrial Respiratory Chain Assays and
Analysis of Mitochondrial Morphology
Mitochondrial respiratory chain assays were undertaken as pre-
viously described.16 Larvae were harvested at 5 dpf (30 per
sample) for initial assessment of mitochondrial function and at
3 dpf to determine the effect of TigarB knockdown on mito-
chondrial function (see below). Mitochondrial respiratory
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complexes were measured in adult muscle tissue of 24-month-
old pink12=2 and wt zebrafish. Mitochondrial morphology was
assessed at 5 dpf in larvae and at 18 months in adult muscle
tissue (see Supplementary Materials and Methods for further
details).
Neurodevelopmental Markers
In situ hybridization was undertaken using probes for Emx1,
sonic hedgehog (shh), Pax2.1, Krox20, and Otpa=Otpb.
Embryos were fixed at 24 hours postfertilization (hpf ),
mounted in glycerol, and photographed using a Zeiss Axio-
plan microscope (Carl Zeiss, Oberkochen, Germany). All
experiments were done in triplicate; a minimum of 10
embryos were used for each genotype per experiment. Islet-1
antibody staining was carried out at 24 hpf as described
previously.16
mRNA Microarray Expression Analysis
RNA was extracted from pink12=2 and wt at 5 dpf. RNA sam-
ples were labeled and hybridized to Agilent Danio rerio 4 3
44K arrays following the manufacturer’s protocols (Agilent
Technologies, Santa Clara, CA). These data were then analyzed
using GeneSpring GX (Agilent), and significant differentially
expressed probes were defined as those with a probability value
< 0.01 (determined by a t test against zero, using the Benja-
mini–Hochberg correction for multiple comparisons) as well as
fold-change between wt and mutant > 2.0 (see Supplementary
Materials and Methods for further details).
qPCR, In Situ Hybridization, and Knockdown
of TigarB
A detailed description of the TigarB qPCR and in situ hybrid-
ization and MO-mediated TigarB knockdown is provided in
the Supplementary Materials and Methods. The sequence of
the TigarB MO (TBMO2) was 50-TAGAGTGTTTATCTACC
TTGCAGCA. The efficacy of the MO was determined by
reverse transcriptase PCR (RT-PCR; forward: 50-GACCAGTA
TTATGCTCACATTTGC-30 and reverse 50-TCTACAGGCTT
GACCTGCTG-30) and gel electrophoresis (see Supplementary
Fig 1). For confirmatory experiments, a pink1 MO was
designed to the exon–intron boundary of exon 5, referred to as
PINK5 (PINK5 sequence: 50-AGAGTCTCTGAGCTCTTAC
TGTTGT). Efficacy was determined using primers forward
50-CTGACTTTGAACGGGCACTT and reverse 50-TCAGGT
GCCATTAGACAGGA. RT-PCR was always performed at 3
dpf on cDNA from control MO-injected, PINK5-injected, and
coinjected PINK5 1 TBMO2 to confirm the knockdown effect
of PINK5. For the coinjection, 7.5ng PINK5 and 7.5ng
TBMO2 were injected simultaneously at single cell stage. RT-
PCR was performed during every technical replicate to deter-
mine the efficacy for both MOs (see also Supplementary Fig 2).
Detection and Inactivation of Microglia
Microglial cells were stained using an in situ probe for apolipo-
protein E (ApoE) as previously described.17 The microglial cells
were then counted in pink2=2 zebrafish larvae and wt controls
at 72 hpf, using a Zeiss Axioplan microscope.
An MO against the myeloid transcription factor pu.1 was
injected at single cell stage to inhibit macrophage maturation
and thus inactivate microglial cells as previously described.18
The number of activated microglial cells was then counted in
anti-pu.1 MO-injected and uninjected pink12=2 larvae as
described above.
Statistical Analysis
All experiments were undertaken in triplicate unless specifically
stated otherwise. Data represent the mean 6 standard error of
the mean. A minimum of 10 embryos were used per genotype
for each replicate experiment. Each treatment group was nor-
malized to the appropriate wild-type control group, and results
were expressed as a percentage of control group mean. One-
way analysis of variance and t tests of significance were used
unless stated otherwise as measures of significance (Prism, ver-
sion 5.0; GraphPad Software, La Jolla, CA).
Results
TILLING Identifies a Truncating Mutation in
pink1 (Y431*)
An N-ethyl-N-nitrosourea (ENU) mutagenized library was
screened for mutations in exons 3, 4, 5, 6, and 7, encoding
the kinase domain of the zebrafish pink1 homologue. A het-
erozygous male was identified from the SM0604 library with
a T to G change at position 1,405 in NM_001008628
(chr23:37574658) in exon 7 (Fig 1A), resulting in a change
from tyrosine to a stop codon at position 431 (Y431*) toward
the end of the kinase domain (see Fig 1B). The mutation was
confirmed with a second, independent method (DdeI restric-
tion digest, data not shown). All experiments and results
reported in this publication were performed on Y431*
mutant fish from the F4 or subsequent generations.
Y431X Mutation Leads to Loss of PINK1
Catalytic Activity and Decreased mRNA Stability
We next investigated the effect of the identified Y431X
truncating mutation on PINK1 kinase activity. We ini-
tially analyzed this mutation in zebrafish PINK1; how-
ever, we were unable to detect any kinase activity of full-
length wild-type zebrafish PINK1 in vitro (Supplemen-
tary Fig 3). It has previously been demonstrated that an
insect orthologue, Tribolium castaneum PINK1
(TcPINK1), exhibits robust kinase activity in vitro as
judged by phosphorylation of substrates including myelin
basic protein (MBP) and the ubiquitinlike (Ubl) domain
of parkin at serine 65.14,19 We therefore modeled the
zebrafish Y431X into TcPINK1 (equivalent to Y419X)
and determined the effect on kinase activity. We found
that the Y419X mutation abolished TcPINK1 activity
against the parkin Ubl domain (see Fig 1C) and MBP
(Supplementary Fig 4). This is consistent with a previous
study that showed that the C terminus of PINK1 is
essential for kinase activity.14 We also hypothesized that
Flinn et al: TigarB and PINK1 Deficiency
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the Y431X mutation results in decreased mRNA stability
due to nonsense-mediated decay. As predicted, compari-
son of pink1 transcript levels in wt and pink12=2
embryos revealed a marked decrease of the pink12=2
transcript by approximately 65% (p < 0.0001) compared
to pink1 transcript levels in wt embryos (see Fig 1D).
Pink12=2 Mutants Have Persistent Loss
of Dopaminergic Neurons
Using in situ hybridization with an antisense RNA probe
for TH, we analyzed the effect of loss of pink1 on dience-
phalic dopaminergic neurons at 5 dpf. The analysis con-
centrated on particular subgroups of dopaminergic neurons
within the diencephalon, namely populations 1, 2, 4, and
5 in the Rink–Wullimann terminology, which are thought
to contain ascending dopaminergic neurons analogous to
those in the mammalian substantia nigra.20,21 The number
of such ascending diencephalic dopaminergic neurons was
reduced by approximately 25% in pink12=2 larvae (p <
0.05; Fig 2). To confirm that the loss of TH positivity was
due specifically to cell loss and not only a reduction of
TH gene expression, we also performed in situ hybridiza-
tion using another marker of dopaminergic neurons,
namely DAT. At 5 dpf, the number of DAT1 diencephalic
neurons in pink12=2 larvae was reduced by approximately
30% when compared to wt (p < 0.01; see Fig 2D), pro-
viding supporting evidence for loss of diencephalic dopa-
minergic neurons in pink12=2 larvae. We next determined
whether this reduction in dopaminergic neurons persists to
adulthood. Two different clusters of dopaminergic neurons
were analyzed, namely the DC3 and DC4 clusters. TH1
neurons in the DC3 cluster are located in the hypothala-
mus and project locally; TH1 neurons in the DC4 cluster
are located in the posterior tuberculum and have long axo-
nal projections to different regions in the brain and spinal
cord, including the telencephalon.22 There was a marked
reduction in the number of ascending dopaminergic neu-
rons in the DC4 cluster (wt 21.9 6 5.9 cells, pink12=2
12.0 6 6.3 cells, p < 0.01; Fig 3); the reduction in the
DC3 cluster failed to reach statistical significance (wt 28.2
6 4.5 cells, pink12=2 17.7 6 4.5 cells, p > 0.05). The
FIGURE 1:
FIGURE 1: Gene and mutation profile of PINK1Y431* zebra-
fish. (A) Chromatograms of wild-type (WT) zebrafish pink1
sequence (upper panel) and homozygous Y431* pink1
sequence (lower panel), with T>G change at position 1,405
in NM_001008628, highlighted in purple. (B) Comparison of
the human PINK1 (top, MTS 5 mitochondrial target
sequence) and WT zebrafish (middle) PINK1 protein struc-
ture as well as the truncated PINK1Y431* protein (bottom).
(C) TcPINK1 Y419X mutation (equivalent to zebrafish
Y431X) leads to loss of kinase activity against parkin ubiqui-
tinlike (Ubl) domain. Y419X TcPINK1 (TcY419X) was assayed
in parallel with WT TcPINK1 (TcWT) and kinase-inactive
TcPINK1 (TcKI). (D) Quantitative polymerase chain reaction
of pink1 transcript levels in wt and pink12=2 embryos; wt
levels were normalized to 100%, whereas those from
pink12=2 embryos were expressed as a percentage of this.
In pink12=2 embryos, the pink1 transcript was reduced by
approximately 65% (65%, ****p < 0.0001) compared to wt.
This suggests that the Y431* mutation causes nonsense-
mediated decay of pink1 mRNA, thus further confirming
that the Y431* mutation results in loss of function of PINK1.
ANNALS of Neurology
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decline in the number of ascending dopaminergic neurons
from 25% reduction at 5 dpf to 50% in 18-month-
old adults could indicate a progressive loss of these ascend-
ing dopaminergic neurons in pink1 mutants from early
development to adulthood, but additional experiments
determining the number of dopaminergic neurons at mul-
tiple time points throughout development and adulthood
are necessary to confirm or refute a progressive nature of
the observed neuronal cell loss.
The Effect of PINK1 Deficiency Is Highly
Specific
Anichtchik et al previously reported that morpholino
antisense mediate knockdown of pink1 in zebrafish
embryos resulted in a “severe developmental phenotype”
with major generalized neurodevelopmental abnormal-
ities.10 In contrast, our pink12=2 embryos did not dis-
play any overt morphological abnormalities. To
investigate further the effect of PINK1 deficiency on cru-
cial neurodevelopmental pathways, detailed in situ
expression analysis was performed, using a panel of neu-
rodevelopmental markers that included Emx1 (expression
predominantly in ventricular zone and mantle of telen-
cephalon), shh (ventral diencephalon, hypothalamus,
basal plate, and floor plate), Pax2.1 (midbrain–hindbrain
boundary), Krox20 (rhombomeres 3 and 5), and Otpa-
Otpb (dopaminergic neurons in the diencephalon).23–28
Both the spatiotemporal expression patterns and the
intensities were identical for all neurodevelopmental
markers in pink2=2 and wt embryos (Supplementary
Fig 5). These data imply that the loss of PINK1 activity
caused by mutational inactivation of the endogenous
gene product does not cause widespread and nonspecific
early neurodevelopmental abnormalities. Additional Islet-1
staining of motor neurons was identical in wt and
pink2=2 embryos, further supporting our assumption that
PINK1 deficiency predominantly exerts its effect on dopa-
minergic neurons (Supplementary Fig 6).
Pink12=2 Mutants Have Reduced Mitochondrial
Complex I and III Activity
Because mitochondrial dysfunction is a key factor in the
pathogenesis of human PINK1-linked PD, we assayed
mitochondrial activity in pink12=2 larvae. Complex I
FIGURE 2: Loss of dopaminergic neurons in pink12=2 larvae.
Representative examples of wt (A) and pink12=2 larvae (B)
after in situ hybridization with a tyrosine hydroxylase (TH)
probe at 5 days postfertilization. Purple coloration indicates
TH1 cells in the brain. Pink12=2 larvae had a lower number
of dopaminergic neurons in Rink–Wullimann groups 1,2, 4,
and 5 (C; *p < 0.05, 2-tailed, unpaired t test using Welch’s
correction). The loss of dopaminergic neurons was confirmed
using a dopamine transport protein (DAT) probe as a further
in situ marker for dopaminergic neurons (D; **p < 0.01).
FIGURE 3: Marked loss of dopaminergic neurons in
pink12=2 adult brain. Representative axial sections of the
DC4 cluster in wt (A) and pink12=2 (B) adult brains are
shown stained with anti–tyrosine hydroxylase antibody.
(C, D) Enlarged images of A and B (area within yellow box),
respectively. There is marked reduction in the number of
dopaminergic neurons in the DC4 cluster of pink12=2 brains
(p < 0.01, 2-way analysis of variance). Scale bars 5 200lm
(A, B) and 50lm (C, D).
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activity was reduced by 78% in pink12=2 larvae com-
pared to wt siblings (p < 0.05; mean 6 standard devia-
tion: wt 2.17 6 0.5, pink12=2 0.49 6 0.1). Complex
III activity was also reduced by 50% (p < 0.05; wt
695.2 6 125, pink12=2 342.4 6 51.2). In contrast,
complex II activity (wt 0.55 6 0.12, pink12=2 0.51 6
0.13, p > 0.05) and complex IV activity (wt 537.1 6
81.9, pink12=2 471.1 6 74.6, p > 0.05) were similar in
wt and pink12=2 larvae (Fig 4).
We next investigated whether mitochondrial dys-
function might increase with ageing by assessing mito-
chondrial respiratory chain activity in muscle tissue of 2-
year-old pink2=2 zebrafish. Neither complex I nor com-
plex III activity showed a further decrease (complex I: wt
3.44 6 0.75, pink12=2 1.47 6 0.5; complex III: wt
296.74 6 67.1, pink12=2 140.5 6 43.3, p < 0.05
when compared to adult wt, p > 0.05 when compared
to pink2=2 larvae; see Fig 4). Similarly, complex II and
complex IV activity remained at comparable levels in
pink2=2 and wt adults (complex II: wt 2.5 6 0.7,
pink12=2 2.6 6 0.6; complex IV: wt 247.3 6 53.2,
pink12=2 258.6 6 82.9).
Mitochondrial Morphology
At 5 dpf, the density or number of mitochondria per
area did not differ significantly between pink12=2 and
wt (ratio 0.52 6 0.13 for mitochondrial area=total area
in pink12=2 vs 0.58 6 0.09 for wt). However, individual
mitochondria were on average 40% larger compared to
wt (pink12=2 0.69lm2, n 5 175, per mitochondrial sec-
tion vs wt 0.49lm2, n 5 174, p < 0.05; Fig 5A, B). We
also observed an increase (47%) in the average mito-
chondrial area per section in pink12=2 mutant adults
(pink12=2 1.37lm2 per mitochondrial section [n 5
228] vs wt 0.93lm2 [n 5 231], p < 0.05; see Fig 5C,
D). Taking these data together, we conclude that PINK1
deficiency results in moderate yet significant alterations
in mitochondrial ultrastructure. Similar to the changes in
mitochondrial function, the increase in mitochondrial
size is already present during early development and is
not further exacerbated through adulthood.
TigarB Upregulation in Pink12=2 Larvae
We next hypothesized that the observed mitochondrial
dysfunction and loss of dopaminergic neurons in
pink12=2 larvae might be influenced by changes in gene
expression. Using an unbiased, array-based, genome-wide
gene expression analysis approach, we identified 274
probes with >2-fold change and p < 0.01 (when cor-
rected for multiple comparisons). One hundred sixteen
probes=108 genes were upregulated (higher in pink12=2
than wt), and 158 probes=146 genes were downregulated
(lower in pink12=2 than in wt; Supplementary Table).
TigarB (ENSDARG00000045858), an orthologue
of TIGAR (ENST00000179259), shares 40% protein
homology and 62% transcript homology to the human
gene and was upregulated more than 12-fold in
pink12=2 embryos in the initial gene array experiments.
TigarB mRNA levels were also increased in pink12=2
embryos in the confirmatory qPCR experiments when
compared to wt after normalization to the housekeeping
gene EF1alpha (2.5-fold upregulation, p 5 0.0003).
Whole mount in situ hybridization analysis revealed a
FIGURE 4: Pink12=2 zebrafish have similar complex I and III
deficiency in early development and adult tissue. Activity of
individual mitochondrial complexes measured relative to the
mitochondrial marker enzyme citrate synthase and
expressed as percentage wild type (%WT), in wt (white
bars) and pink12=2 (black bars) embryos at 5 days postferti-
lization as well as wt and pink12=2 adult muscle tissue.
Complex I and complex III activity in pink12=2 embryos is
significantly lowered (*p < 0.05); this defect is still present
in adult pink12=2 muscle (*p < 0.05). However, the magni-
tude of the defect does not change when comparison is
made between pink12=2 embryos and pink12=2 adult zebra-
fish (complex I, p 5 0.09; complex III, p 5 0.7). Complex II
and IV activity remain unchanged in both pink12=2 embryos
and pink12=2 mutant adults.
ANNALS of Neurology
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marked upregulation of TigarB in pink12=2 brains as
early as 24 hpf (Fig 6). Zebrafish possess an additional
TIGAR orthologue, TigarA (ENSDARG00000051749),
which shares 40% protein homology with the human
TIGAR gene, but this transcript did not show a change
in the microarray experiments (data not shown).
To investigate the functional significance of TigarB
upregulation, an MO (TBMO2) designed to disrupt
TigarB splicing was injected into single cell stage
pink12=2 embryos and wt controls (see Supplementary
Fig 1). This MO-mediated inactivation of TigarB
resulted in complete rescue of dopaminergic neurons in
pink12=2 larvae at 3 dpf (Fig 7, top). To further validate
the rescue effect of TigarB knockdown in PINK1 defi-
ciency, confirmatory double-knockdown experiments
were undertaken in wt zebrafish embryos. Coinjections
were undertaken with PINK5, an MO directed against
the exon–intron boundary of exon 5, and the TigarB
MO TBMO2. PINK5 MO-mediated pink1 knockdown
led to a reduction of the dopaminergic neurons by
approximately 20% at 3 dpf (p 5 0.01), similar to the
observed reduction of dopaminergic neurons in the stable
pink1 mutant line. Coinjection of the MOs PINK5 and
TBMO2 again completely rescued the dopaminergic
neurons (see Fig 7, bottom).
We hypothesized that this rescue may be due to
normalization of mitochondrial function after TigarB
inactivation and therefore assessed the activity of the
individual complexes of the mitochondrial respiratory
chain in pink12=2 larvae. As predicted, both complex I
activity and complex III activity were normalized in
pink12=2 larvae after TigarB inactivation (Fig 8).
Microglial Activation
Abnormal expression of innate immunity genes precedes
dopaminergic deficits in PINK1-deficient mice.29 Moderate
microgliosis was reported in the only postmortem report
on a brain of a PD patient with 2 PINK1 mutations.30 Of
note, several of the markedly upregulated genes in our
gene expression analysis (see see Supplementary Table),
such as complement factor H and calpain, are involved in
immune mechanisms and activation of microglial cells.31
Using an ApoE in situ probe as a microglial marker, we
compared the number of microglial cells in wt and
pink12=2 zebrafish larvae.17 There was a marked increase
in microglial activation in the pink12=2 embryos at 3 dpf
(pink12=2 32.3 6 4.7 microglial cells per embryo, wt
20.0 6 0.82, p < 0.05; Fig 9). Microglial development
can be completely abolished in zebrafish embryos using an
MO targeting the transcription factor pu.1 (Supplementary
Fig 7).32 We postulated that inactivation of microglia
resulting from MO-mediated pu.1 knockdown might have
a protective effect on the dopaminergic neurons in the
pink12=2 embryos. However, there was no difference in
the number of dopaminergic neurons between uninjected
and pu.1 MO-injected pink12=2 larvae (number of dopa-
minergic neurons in pu.1 MO-injected pink12=2 embryos:
26.5 6 1.36; number of dopaminergic neurons in unin-
jected pink12=2 embryos: 25.0 6 1.55, p > 0.05). This
suggests that the observed microglial activation may be a
downstream mechanism involved in clearing already dam-
aged or dead dopaminergic neurons, rather than a crucial
upstream mechanism leading to the loss of dopaminergic
neurons in PINK1 deficiency.
Discussion
Genetic research has provided crucial new insight into the
pathogenesis of PD, but the precise mechanisms leading
FIGURE 6: TigarB is expressed in brain tissue and upregu-
lated in pink12=2. Whole mount in situ hybridization was
performed using a riboprobe specific for TigarB expression.
TigarB expression was largely limited to the brain. Pink12=2
embryos show a marked increase in TigarB expression (bot-
tom panels) compared to wt (top panels) throughout devel-
opment. hpf 5 hours postfertilization.
FIGURE 5: Mitochondria are enlarged in both larval (B) and
adult (D) pink12=2 tissue compared to larval (A) or adult (C)
wt control tissue. Electron microscopy sections of muscle
tissue in 5-day-old zebrafish larvae and 2-year-old adult
zebrafish are shown. The average size of the mitochondria
was larger in both pink12=2 larvae and adult tissue (p <
0.01; 2-sided Student t test). In adult pink12=2 tissue, some
mitochondria had considerably higher electron density than
others (D).
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to neuronal cell death remain to be elucidated.33 Recessive
loss of function mutations in autosomal genes such as par-
kin, PINK1, or DJ-1 are associated with inherited forms
of EOPD. Conditional knockout of parkin in adult
rodents leads to progressive loss of dopaminergic neurons,
but classical parkin, Pink1, or DJ-1 knockout mice do not
develop loss of dopaminergic neurons, hampering investi-
gation of their pathogenic effects especially in early stages
of brain development.6,34 By contrast, our pink2=2 zebra-
fish display loss of dopaminergic neurons as well as other
key features of the disease, such as impaired mitochondrial
function and morphology as early as 5 dpf, thus providing
a tractable vertebrate genetic model for EOPD. The
FIGURE 7: Morpholino antisense oligonucleotide (MO)-medi-
ated knockdown of TigarB results in rescue of dopaminergic
neurons. Tyrosine hydroxylase neurons were counted at 3
days postfertilization (dpf) and expressed as a percentage
of wt uninjected mean. TigarB knockdown in wt embryos
(30 6 2.92, WT TBMO2) resulted in a small increase of 5%
compared to wt uninjected (28 6 1.21, WT), but this did
not reach statistical significance (p > 0.05). The pink12=2
uninjected embryos displayed a similar decrease in the num-
ber of dopaminergic neurons (22.8 6 1.3, PINK12=2) as
observed at 5 dpf (see Fig 2) of approximately 20% (*p 5
0.04, PINK12=2), but MO knockdown of TigarB in pink12=2
embryos completely rescued the dopaminergic neurons
(29.2 6 2.6, **p 5 0.01, PINK1 TBMO2, top panel). In con-
firmatory experiments, coinjections of an MO directed
against pink1 (PINK5) and Tigar (TBMO2) again completely
rescued the dopaminergic neurons in pink1-deficient zebra-
fish embryos (bottom, **p < 0.01).
FIGURE 8: Spectrophotometric measurement of complex I
activity was lower by 55% in pink12=2 zebrafish (black bars)
compared to wt sibling embryos (white bars) at 3 days post-
fertilization, and recovered to normal levels in pink12=2
zebrafish with TigarB knockdown (gray bars; wt 8.07 6
0.25, wt with TigarB knockdown [second white bar] 8.618 6
1.11, pink12=2 3.67 6 0.99, pink12=2 TigarB morpholino
antisense oligonucleotide 10.98 6 1.67, *p < 0.05). Com-
plex III activity was similarly reduced by 55% in pink12=2
zebrafish compared to wt sibling embryos, and recovered
to normal levels in pink12=2 zebrafish with TigarB knock-
down (wt 796 6 52, wt with TigarB knockdown 695 6 29,
pink12=2 351 6 106, pink12=2 with TigarB knockdown 749
6 228, *p < 0.05).
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precise projection of the dopaminergic neurons in the pos-
terior tuberculum is still a matter of debate.20,35,36 How-
ever, all studies using zebrafish as an animal model for PD
have universally observed a loss of dopaminergic neurons
in the posterior tuberculum after PD toxin exposure such
as treatment with MPP1 and frequently also after MO-
mediated transient PD gene knockdown.11,37 The func-
tional relevance of the Y431X mutation was confirmed in
kinase activity assays but also by studying the effect of this
Y431X mutation on pink1 transcript levels.
Importantly, our data also suggest that both mito-
chondrial dysfunction and changes in mitochondrial
morphology are early, specific consequences of PINK1
deficiency that do not progress further with age.
TIGAR is a bisphosphatase that lowers fructose-2,6-
biphosphate (Fru-2,6-P2) levels in cells, resulting in an
inhibition of glycolysis and an overall decrease in intracel-
lular reactive oxygen species via increased production of
nicotinamide adenine dinucleotide phosphate through the
pentose phosphate shunt.13 Recombinant human and
zebrafish TIGAR have similar catalytic activity.38
Increased substrate provision normalizes impaired mito-
chondrial respiration in PINK1 deficiency.39 Further
studies are needed to determine whether decreased sub-
strate provision for mitochondrial respiration via TIGAR-
mediated inhibition of glycolysis may contribute to this
relative substrate deficiency in the absence of PINK func-
tion. More recently, TIGAR has also been identified as a
negative regulator of mitophagy.40 TIGAR upregulation
results in an increased number of enlarged mitochondria
in mice, comparable to the mitochondrial enlargement
identified in our pink12=2 zebrafish.40 Impaired mitoph-
agy is currently considered to be a crucial mechanism in
the pathogenesis of early onset PD.41 The observed
TigarB upregulation in pink12=2 zebrafish now suggests
that additional mechanisms other than impaired PINK1-
mediated recruitment of parkin to damaged mitochondria
may contribute to impaired mitophagy in PD.42 The res-
cue of dopaminergic neurons in pink12=2 zebrafish after
TigarB inactivation was confirmed using a complemen-
tary, MO-mediated pink1 knockdown approach.
The complete normalization of mitochondrial func-
tion and resulting rescue of ascending dopaminergic neu-
rons after antisense-mediated TigarB inactivation suggests
that modulation of TIGAR-mediated mechanisms may
be a promising strategy for disease-modifying therapy.
TIGAR is typically activated by p53. Our data therefore
provide a further intriguing link between neurodegenera-
tion and cancer-related mechanisms.43,44
Both the extent of microglial activation and the
lack of a protective effect of microglia on the loss of the
dopaminergic neurons in pink12=2 embryos were some-
what surprising. Our data suggest that microglial activa-
tion is—at least in this model—more likely to reflect
either nonspecific activation or a limited role for micro-
glia in the clearing of cell debris.
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